CCDC92

Across TCGA pan-cancer cohorts, CCDC92 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC92 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CCDC92 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC92 expression acts as an unfavorable survival marker.

CESC, LIHC, and STAD are the cancer types where CCDC92 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.144	0.705	.004	24	view →
LIHC	OS	Median	All	0.168	0.779	<.001	18	view →
STAD	OS	Median	All	0.003	0.667	<.001	18	view →
SKCM	OS	Median	All	0.714	0.874	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCDC92–CESC (DFS)

Open the CESC breakdown →